ArticleCurrent topics in medicinal chemistry2026
Discovery of Anoikis-correlated Biomarkers for Ovarian Cancer Through Integrated Transcriptome and Single-cell RNA Sequencing Analyses.
Article in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOvarian cancer (OC) is a heterogeneous cancer with a high death rate and poor prognosis. Identifying precise and reliable prognostic biomarkers is crucial for the treatment of OC.
methodsAnoikis-related DEGs were screened from the differentially expressed genes (DEGs) between the OC group and the control group and then subjected to functional enrichment analysis. A protein-protein interaction (PPI) network was developed to obtain candidate genes. Then, LASSO regression and support vector machine-recursive feature elimination (SVM-RFE) analysis were employed to select biomarkers, followed by conducting gene set enrichment analysis (GSEA). Correlations between the biomarkers and immune infiltration, drug sensitivity, and immunotherapy response were assessed by the Spearman method. The expression of the biomarkers in cells was measured by scRNA-seq analysis.
resultsWe obtained 142 anoikis-related DEGs, which were mainly enriched in apoptosis-relevant pathways. A total of 16 candidate genes were acquired from the PPI network. Then, STAT3 and BCL2L1 were selected via LASSO regression and SVM-RFE analysis as two biomarkers for OC. BCL2L1 was closely associated with the infiltration of 5 immune cell types and 32 drugs, while STAT3 exhibited notable correlation with the infiltration of 6 immune cell types and 13 drugs. The Tumor Immune Dysfunction and Exclusion (TIDE) score was positively correlated with the two biomarkers. Moreover, STAT3 and BCL2L1 were expressed in most cells, with a high expression of STAT3 in endothelial cells. DISCUSSION: This study integrated bulk and single-cell transcriptomics to identify STAT3 and BCL2L1 as two anoikis-related biomarkers linked to the immune infiltration and drug sensitivity of OC, showing potential value for patient stratification and therapy. These findings suggested that targeting the STAT3/BCL-xL axis and combinational immunotherapy might be an effective strategy for OC treatment, which, however, should be further verified by functional and clinical experiments.
conclusionThis study identified two anoikis-related biomarkers for OC, contributing to the clinical diagnosis of OC and its treatment.
Indexed as
Identifiers
41582369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.